Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

IMPORTANCE: Poly(adenosine diphosphate–ribose) polymerase inhibitor and anti–programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC). OBJECTIVE: To evaluate the clinical activity (primary) and safety (secon...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Oncol
Egile Nagusiak: Vinayak, Shaveta, Tolaney, Sara M., Schwartzberg, Lee, Mita, Monica, McCann, Georgia, Tan, Antoinette R., Wahner-Hendrickson, Andrea E., Forero, Andres, Anders, Carey, Wulf, Gerburg M., Dillon, Patrick, Lynce, Filipa, Zarwan, Corrine, Erban, John K., Zhou, Yinghui, Buerstatte, Nathan, Graham, Julie R., Arora, Sujata, Dezube, Bruce J., Telli, Melinda L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2019
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567845/
https://ncbi.nlm.nih.gov/pubmed/31194225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1029
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak